Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q18 and 2018.
| MONTEVIDEO, Uruguay, March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q18 and 2018. HIGHLIGHTS Net revenues for 2018 increased by 10% in constant currency, positively impacted by Dosa, marking BRL 821M (including hyperinflation adjustment). Gross profit increased by 12% vs. 2017, in constant currency. Gross margin of 51% (including hyperinflation adjustments) vs. 54% in 2017. OPEX are in line with 34% of net revenues in 2018. Adjusted EBITDA increased by 12% in constant currency vs. 2017. Adjusted EBITDA margin came to 22% in 2018 (including hyperinflation adjustment), vs. 24% in 2017. Net income totaled BRL 63M in 2018 (including hyperinflation adjustment) vs. BRL 17M in 2017. Adjusted net income up 42% vs. 2017, in constant currency. Strategic agenda evolved with the ongoing execution of the pipeline. Recently launched products growing over 100%, with the performance of new products such as LENVIMA, ABRAXANE and Gilead portfolio. Contacts:
SOURCE Biotoscana Investments S.A | ||
Company Codes: Luxembourg:BIO, SaoPaulo:GBIO33 |
View original content:
